Summary
Morbiusmay be one of the weakestMarvelmovies ever, but its box office performance makes five other movies seem even worse. Part ofSony’s Spider-Man Universe,Morbiusearned $167.5m at the global box office - a surprisingly high figure considering its reputation. This performance has drawn comparison with other Marvel movies, fromthe MCU timelineand beyond, and offers a fresh perspective on some classic comic book movies.
2022’sMorbiusfollowed Dr. Michael Morbius (Jared Leto), who transforms into a vampire-like creature while attempting to cure himself of a rare blood disease. Despite its intriguing premise and high expectations,Morbiusfaced significant challenges and performed poorly.Morbiushas since gained a notorious reputation as one of the worst comic book movies ever. However, despite this,Morbius’s box office performance still makes five Marvel movies seem even worse.
Morbius Ending & Marvel Movie Future Explained (In Detail)
Sony’s Morbius leaves a few plot threads hanging, with the ending setting up quite a few things for the future. We break down the ending in detail.
Morbius' Box Office Beats 5 Marvel Movies
Despite its struggles,Morbiusmanaged to earnmore at the global box office than five other Marvel movies, making these movies seem even worse by comparison.Morbiusout-performedGhost Rider: Spirit of Vengeance,Elektra,The Punisher,The New Mutants, andPunisher: War Zone(viaThe Numbers). This outcome is intriguing, particularly when considering the historical and contextual factors involved.
Morbius' Most Controversial Scene Makes Even Less Sense 1.5 Years Later
Morbius' post-credits scene has become infamous for not making sense, and it gets worse as Sony continues to ignore it and Vulture’s future.
First, it’s important to note that most of these movies were released over a decade ago, except forThe New Mutants.Inflation and the general increase in movie ticket prices over the years played a role in boostingMorbius’s earnings.This economic factor means thateven a moderate box office performance in recent years can surpass the earnings of older filmswhen adjusted for inflation.
$62, 759, 437
$149,217,355
$56,824,633
$54,533,774
$44,608,247
Punisher: War Zone (2008)
$10,157,534
Additionally, the evolving landscape of superhero movies provides another layer of context. WhenElektra,The Punisher, andPunisher: War Zonewere released, the superhero genre was not as dominant or as finely tuned as it is today. The expectations and production values were different, andthe Marvel Cinematic Universe hadn’t yet set the high standardsthat contemporary audiences had come to expect.Morbius, while not part of the MCU, still benefited from the overall popularity of Marvel-branded movies.
Morbius Cast & Marvel Character Guide
Morbius' cast is small, but many of the actors are familiar to fans. We preview the cast, which characters they play & other projects they’re in.
The increased visibility and interest in Marvel properties likely contributed to its relatively better performance compared to these earlier releases. Ultimately, though, this box office history does offer a new perspective on these five Marvel movies, making them seem even worse than viewers might remember. Nevertheless, this comparisonoffers an interesting insight into the evolution of the superhero genreand highlights how changes in the industry, audience expectations, and economic factors can influence box office outcomes.
Why Morbius' Box Office Was So Low
Morbiusfaced significant challenges that contributed to its poor performance at the box office. Initially slated for release in July 2020,Morbiuswas subjected to numerous delays due to the COVID-19 pandemic, finally hitting theaters in April 2022. This timing was critical asthe film industry was still grappling with the aftermath of the pandemic, with many theaters closed or operating under restrictions and audiences gradually returning to cinemas.
Morbius, a lesser-known character from the Spider-Man universe, struggled to attract a broad audience. Unlike more prominent Marvel characters,Morbius lacked widespread recognition, and his connection to Spider-Man was tenuous in this standalone film. This detachment from the more popular Spider-Man narrative made it harder to draw in fans who were unfamiliar with the character’s comic book origins.
All Marvel Movies Releasing In 2024
The Marvel movies releasing in 2024 offer a range of film experiences - and some confusion, due to the changed dates of several incoming installments.
Compounding these issues,Morbiusreceived overwhelmingly poor reviews from critics, who cited its weak plot, lackluster special effects, and uninspired performances. These negative reviews were quicklyamplified by fervent word of mouth and social media, resulting in a plethora of memes that mocked the film’s shortcomings. This viral spread of criticism and satire severely damaged the movie’s reputation, deterring potential viewers. The combination of these factors created a perfect storm that underminedMorbiusat the box office, leading to its disappointing financial performance.
Morbius' Total Gross Puts The MCU’s Lowest Box Office In Perspective
Morbius’s box office performance highlights how even the least successful movies in the Marvel Cinematic Universe maintain a reasonable standard in comparison. A prime example isThe Marvels, which, despite receiving unfavorable reviews, outperformedMorbiusfinancially. Thisunderscores the inherent quality and audience draw of MCU films, even at their weakest.The Marvelsmanaged to attract a substantial audience, reflecting the MCU’s established reputation for delivering engaging and interconnected stories.
This reputation often results in a baseline level of success, buoyed by a loyal fanbase and consistent marketing strategies. Conversely,Morbiusfailed to leverage its potential. WhileThe Marvelsdid not achieve critical acclaim, its relative box office success compared toMorbiusexemplifies howthe MCU maintains a benchmark of quality that even its lesser films meet, reinforcing the disparity between MCU productions and other superhero film ventures.
